Conference Call with Ajanta Pharma Management and Analysts on Q4FY25 & Full Year Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Ajanta Pharma announced Q4FY25 & FY25 results Q4FY25 FInancial Highlights: Revenue from operations at Rs 1,170 crore against Rs 1,054 crore; up 11%. EBITDA at Rs 297 crore against Rs 278 crore; up 7%; EBITDA at 25%. Profit after tax at Rs 225 crore against Rs 203 crore; up 11%; PAT at 19%. FY25 FInancial Highlights: Revenue from operations at Rs 4,648 crore against Rs 4,209 crore; up 10%. EBITDA at Rs 1,260 crore against Rs 1,172 crore; up 7%; EBITDA at 27%. Profit after tax at Rs 920 crore against Rs 816 crore; up 13%; PAT at 20%. Cashflow from operations (CFO) was Rs 1,157 crore, EBITDA to CFO conversion of 92%. Free cashflow (FCF) was Rs 694 crore, FCF to PAT conversion of 75%. ROCE stood at a healthy level of 32% and RONW at 25%. Result PDF